California Department of Cannabis Control Attorney Fee Petition Mechanics: Tyler Odyssey Civil Complaint Date as Primary Welch Anchor, DCC License Search Database as Secondary Institutional Anchor (the Only DCC License Search Database Anchor in This Series — DCC Is a Standalone California State Department Created by AB 141 [2021], Distinct from All DCA Board Databases — Covering Retailer, Delivery, Microbusiness, Distributor, Manufacturer, Cultivator, and Testing Laboratory License Types by License Number, Issue Date, and Active/Cancelled Status), CLRA § 1780 Mandatory Attorney Fees for California Consumers Who Purchased Unlicensed Cannabis Products Lacking Required COA Batch Testing Under 4 CCR § 5724 Including Consumers Exposed to Uncontrolled Pesticide Residue, Heavy Metal, Microbial, and Residual Solvent Contamination in Untested Products

Statutory Framework: Bus. & Prof. Code § 26038 and MAUCRSA — DCC License Requirements, Prohibited Conduct, and CLRA § 1780 Mandatory Attorney Fees for Unlicensed Cannabis Retail Practice

California Business and Professions Code § 26038 is the operative licensure prohibition of MAUCRSA — the Medicinal and Adult-Use Cannabis Regulation and Safety Act (Bus. & Prof. Code §§ 26000–26202) — establishing that no person shall engage in commercial cannabis activity without a state license issued under MAUCRSA, and that any person who engages in commercial cannabis activity without such a license is subject to civil penalties, criminal penalties, and civil liability to consumers. MAUCRSA was enacted following Proposition 64 (the Adult Use of Marijuana Act, approved by California voters in November 2016) and Proposition 215 (the Compassionate Use Act, 1996, codified at Health & Safety Code § 11362.5), which together established California's dual adult-use and medicinal cannabis framework. The DCC (California Department of Cannabis Control) is the state department created by AB 141 (2021), which unified the three prior California cannabis licensing agencies — the Bureau of Cannabis Control (BCC), the California Department of Food and Agriculture (CDFA) cannabis program, and the California Department of Public Health (CDPH) cannabis program — under a single regulatory authority with jurisdiction over all commercial cannabis license types. § 26038(a) provides that "[a]ny person engaging in commercial cannabis activity without a license required under this division shall be subject to civil penalties of up to three times the amount of the license fee for each violation" and further that the person "shall be guilty of a misdemeanor punishable by imprisonment in a county jail not to exceed six months or by a fine not to exceed five hundred dollars ($500), or by both such fine and imprisonment." § 26038(b) and the broader MAUCRSA framework establish that consumers who purchase cannabis goods from unlicensed retailers have civil claims under CLRA § 1780 and UCL § 17200 for the credential misrepresentation and product safety harm resulting from the absence of state-required COA batch testing.

The scope of "commercial cannabis activity" subject to § 26038 licensure requirements encompasses every stage of the cannabis supply chain that MAUCRSA regulates: (1) retail cannabis sales — both storefront retail (Type 10 Retailer license) and non-storefront delivery-only retail (Type 9 Non-Storefront Retailer license); (2) cannabis delivery services operating without a Type 9 or Type 10 license with delivery authorization — including unlicensed delivery services that accept orders through apps, websites, or phone and dispatch delivery drivers without state licensure; (3) microbusiness operations — entities engaging in multiple commercial cannabis activities (cultivation up to 10,000 square feet, manufacturing, distribution, and retail) at the same premises, which require a Type 12 Microbusiness license; (4) cannabis manufacturing — the production of cannabis-infused products (edibles, beverages, concentrates, vaporizer cartridges, topicals) using solvent-based extraction (Type 6) or non-solvent-based processes (Type N), requiring the appropriate DCC manufacturer license; (5) cannabis distribution — the licensed transportation and distribution of cannabis goods between licensees in the supply chain, which requires a Type 11 Distributor license and is the critical distribution link through which COA-tested cannabis goods flow from cultivators and manufacturers to retailers; (6) cannabis cultivation — all cultivation tiers from specialty indoor to large outdoor cultivation, each requiring the applicable cultivation license type; and (7) cannabis testing laboratory operations — the Type 8 Testing Laboratory license required to conduct mandatory COA batch testing under 4 CCR § 5724; a testing laboratory that operates without a Type 8 license produces COA certificates that are legally invalid, and a retailer that relies on COA certificates from an unlicensed testing laboratory is itself in violation of MAUCRSA's supply chain requirements.

The CLRA civil remedy arises because cannabis goods and delivery services are consumer goods and services purchased by California consumers for personal use, satisfying the definition of "consumer goods" and "consumer services" under Civil Code §§ 1761(a) and 1761(b). Every cannabis retailer or delivery service that operates without a DCC license but presents itself to consumers as a licensed cannabis operation — through storefront signage, website representations, app listings on cannabis marketplaces, or delivery packaging that mimics licensed cannabis branding — impliedly represents current DCC licensure, a representation that constitutes a misrepresentation of service provider qualifications under Civil Code § 1770(a)(14) when the retailer lacks a current DCC license. The additional COA testing failure compounds the CLRA claim: consumers who purchase cannabis goods from unlicensed retailers are simultaneously receiving goods that have never undergone the mandatory pesticide, heavy metal, microbial, mycotoxin, residual solvent, and water activity testing required under 4 CCR § 5724 — a product characteristic misrepresentation under Civil Code § 1770(a)(7) (misrepresentation of goods as being of a particular standard, quality, or grade when they are of another). Section 1780(e)'s "shall award" language eliminates all judicial discretion and establishes CLRA § 1780 as a pure mandatory fee statute for unlicensed cannabis retailer practice claims. UCL § 17200 provides a parallel per se unlawful business practice theory supporting restitution of all fees paid to the unlicensed retailer and injunctive relief against continued unlicensed operations and credential misrepresentation.

Three Unique Distinctions in the Fee-Petition-Mechanics Series

• THE ONLY DCC (California Department of Cannabis Control) License Search Database anchor in the entire fee-petition-mechanics series — the DCC was created as a standalone California state department by AB 141 (2021), consolidating multiple prior cannabis licensing programs, and is entirely distinct from all DCA board databases, all DCA bureau databases, the CDI License Search, all CDPH databases, and all CDFA databases: the DCC License Search is the only secondary anchor in the series tied to California's cannabis licensing authority — a database that covers all commercial cannabis license types issued under MAUCRSA, recording each licensee's complete DCC license record: DCC license number (the unique identifier assigned to each licensed commercial cannabis operation — DCC license numbers follow a license-type-specific alphanumeric format, such as "C10-0000001-LIC" for a Type 10 Retailer or "C9-0000001-LIC" for a Type 9 Non-Storefront Retailer); legal business name (the entity name on the DCC license application, which may differ from the DBA or trade name under which the retailer presents to consumers); DBA/trade name (the public-facing operating name, critical for matching the defendant's consumer-facing brand to the DCC license record); license type (the specific MAUCRSA license category: Type 10 Retailer for storefront cannabis retail open to the public; Type 9 Non-Storefront Retailer for delivery-only cannabis retail without a physical storefront accessible to the public — the license type most frequently involved in unlicensed cannabis delivery schemes; Type 12 Microbusiness for multi-activity cannabis operations conducting cultivation, manufacturing, distribution, and retail at the same licensed premises; Type 11 Distributor for the licensed transportation and distribution of cannabis goods between licensees in the supply chain; Type 6 Manufacturer using solvent-based extraction processes; Type N Manufacturer using non-solvent-based processes; Type 1A Indoor Specialty Cultivation; Type 1B Indoor Small Cultivation; Type 2A Outdoor Specialty Cultivation; Type 2B Outdoor Small Cultivation; Type 3A Indoor Medium Cultivation; Type 3B Outdoor Medium Cultivation; Type 4 Nursery; Type 5A Large Indoor Cultivation; Type 5B Large Outdoor Cultivation; Type 8 Testing Laboratory required for all mandatory COA batch testing; Type 14.1 Events Organizer for cannabis events); premises address (the physical location of the licensed commercial cannabis premises, used to confirm that the defendant's operating location matches or does not match any DCC-licensed premises); license issue date (the date the DCC issued the license — confirming whether the defendant was licensed during the period when the plaintiff consumer made cannabis product purchases); expiration date (DCC cannabis licenses require annual renewal — failure to renew by the expiration date renders the license Cancelled, and a retailer operating after the expiration date is engaged in unlicensed commercial cannabis activity under § 26038 even if it previously held a valid DCC license); and current status: Active (license in good standing, authorized for commercial cannabis activity); Annual Renewal (license currently in the annual renewal process — the licensee may continue operating during the Annual Renewal period); Suspended (DCC has issued a suspension order pursuant to DCC enforcement action — the licensee is not authorized to engage in commercial cannabis activity during the suspension period); Revoked (DCC has revoked the license following administrative disciplinary proceedings — the most severe DCC enforcement status; a revoked licensee may not engage in commercial cannabis activity unless and until the DCC grants a reinstatement petition); Cancelled (the licensee voluntarily surrendered the license or failed to complete the annual renewal process within the required timeframe — a Cancelled license holder is engaged in unlicensed commercial cannabis activity under § 26038 if they continue operating after cancellation); the DCC License Search is structurally distinct from every other California licensing database in the fee-petition-mechanics series because it covers a single state department's jurisdiction over an entire industry's commercial supply chain — from seed (cultivator) to sale (retailer) — rather than the individual professional practitioner licenses issued by DCA boards, DCA bureaus, and other California professional licensing authorities; an attorney verifying the defendant's DCC licensure status searches the DCC License Search by business name, address, or license number and receives a record confirming whether the defendant holds an Active DCC license for the specific commercial cannabis activity being performed at the specific location where the plaintiff consumer purchased or received cannabis goods.
• THE ONLY page where unlicensed practice involves selling cannabis goods that lack required COA (Certificate of Analysis) batch testing under 4 CCR § 5724 — exposing consumers to uncontrolled pesticide residue, heavy metal, microbial pathogen, and residual solvent contamination in untested products: California's licensed cannabis supply chain requires that every batch of cannabis goods pass a comprehensive mandatory laboratory testing panel — conducted by a DCC-licensed Type 8 testing laboratory — before the batch may be distributed or sold to California consumers; 4 CCR § 5724 specifies the complete mandatory testing panel that each batch must pass before it enters the licensed distribution and retail chain: (a) potency analysis — THC, CBD, and minor cannabinoid content (CBG, CBN, THCA, CBDA, delta-8 THC) must be accurately measured and disclosed on product labeling; (b) residual solvents and processing chemicals — analysis for residual hydrocarbon solvents (butane, propane, pentane, hexane), CO2, ethanol, and other extraction solvents used in cannabis concentrate manufacturing; action levels are set per 4 CCR § 5724(f), and batches exceeding action levels must fail the testing panel and be remediated or destroyed; (c) microbial contaminants — the testing panel covers total aerobic plate count (TAPC), total yeast and mold (TYM), total coliform bacteria, Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus terreus, Salmonella spp., and pathogenic Escherichia coli; the Aspergillus testing requirement is critical for immunocompromised cannabis consumers (cancer patients undergoing chemotherapy, HIV/AIDS patients, organ transplant recipients on immunosuppressive therapy) who use cannabis for symptom management — Aspergillus species are opportunistic mold pathogens that cause invasive aspergillosis (a potentially fatal fungal pneumonia) in severely immunocompromised individuals, and California's cannabis Aspergillus action levels reflect the heightened risk to this consumer population; (d) mycotoxins — aflatoxin B1, aflatoxin B2, aflatoxin G1, aflatoxin G2, and ochratoxin A; aflatoxins are potent hepatotoxins and human carcinogens produced by Aspergillus mold species that contaminate agricultural crops (including cannabis) under humid storage conditions; ochratoxin A is a nephrotoxin produced by Aspergillus and Penicillium species; (e) pesticides — a comprehensive pesticide panel covering organophosphate insecticides, carbamate insecticides, synthetic pyrethroid insecticides, organochlorine insecticides, and other agricultural chemical categories; California's cannabis pesticide action levels (set at 4 CCR Appendix A) are among the strictest agricultural pesticide standards in the nation, with action levels for many pesticide analytes set at parts-per-billion levels; the pesticide testing requirement is particularly critical because many pesticides registered for use on other agricultural crops are not registered for use on cannabis — including myclobutanil (a fungicide that converts to hydrogen cyanide when heated to cannabis vaporization or combustion temperatures, posing acute cyanide poisoning risk to consumers who smoke or vaporize contaminated cannabis; myclobutanil is commonly detected in unregulated cannabis cultivation operations); bifenazate (a miticide that when heated produces acequinocyl, a toxic combustion product); abamectin (a macrocyclic lactone acaricide not registered for cannabis); chlorpyrifos (an organophosphate neurotoxin banned from food crops in California under Senate Bill 637 but still used in unregulated cannabis grows); and spiromesifen (a lipid biosynthesis inhibitor not registered for cannabis); illegal cannabis cultivation operations routinely use these prohibited pesticides at concentrations far exceeding California's cannabis pesticide action levels — because unlicensed cultivators have no financial incentive to comply with action level requirements and no requirement to test their product before sale; (f) foreign material — visual inspection for seeds, stems, insects, mold visible to the naked eye or under low magnification; (g) water activity and moisture content — cannabis goods with water activity above the action level are subject to microbial contamination risk from residual moisture; (h) heavy metals — arsenic, cadmium, lead, and mercury; limits set at 4 CCR § 5724(g); heavy metal contamination in cannabis is associated with the growing substrate — contaminated soil, compost, or hydroponic nutrient solutions can cause heavy metal bioaccumulation in cannabis flower and concentrate; lead and arsenic are of particular concern in contaminated urban soil grows and in some imported growing media; (i) terpenoid profile — informational terpene content analysis; the mandatory COA testing panel is the complete product safety assurance mechanism for California cannabis consumers — a consumer who purchases cannabis goods from a DCC-licensed retailer can be confident that every batch of product on the licensed retailer's shelves passed the 4 CCR § 5724 testing panel from a DCC-licensed Type 8 laboratory before reaching the retail shelf; an unlicensed retailer purchases products from unlicensed cultivators and unlicensed manufacturers who have no obligation to conduct this mandatory testing panel — and who have every financial incentive to avoid the cost and delay of third-party laboratory testing; the consumer who purchases from an unlicensed retailer receives a cannabis product with no COA, no disclosure of contamination status, no potency verification, and no assurance that the product does not contain pesticide residues, heavy metals, microbial pathogens, or mycotoxins at concentrations harmful to human health.
• THE ONLY page where unlicensed practice involves a federally Schedule I controlled substance — creating a dual-jurisdiction enforcement context where California DCC licensing violations under § 26038 occur simultaneously with federal Controlled Substances Act (21 U.S.C. § 801 et seq.) Schedule I distribution violations, but where the California CLRA § 1780 consumer protection claim and Ketchum multiplier remain fully operative because California has authorized commercial cannabis activity for California consumers and the federal enforcement posture has been to defer to state enforcement in states with robust regulatory systems: cannabis is a Schedule I controlled substance under 21 U.S.C. § 812, Schedule I(c)(10) — meaning federal law treats cannabis as a substance with "a high potential for abuse," "no currently accepted medical use in treatment in the United States," and "a lack of accepted safety for use under medical supervision"; every commercial cannabis transaction — even a fully DCC-licensed California retail sale — is simultaneously a violation of the federal Controlled Substances Act under 21 U.S.C. §§ 841(a)(1) (distribution of a Schedule I controlled substance) and 844(a) (possession); the § 26038 unlicensed cannabis retailer is simultaneously violating California state law and engaging in federal controlled substance distribution offenses; however, the dual-jurisdiction context does not defeat the California CLRA § 1780 consumer protection claim for the following reasons: (1) the CLRA § 1780 claim does not require the court to recognize the legality or enforceability of the cannabis sales transaction under federal law — the claim is that the defendant misrepresented their qualifications as a state-licensed commercial cannabis retailer under Civ. Code § 1770(a)(14) and delivered products that lacked the state-required safety testing and quality certification required under 4 CCR § 5724; (2) federal preemption analysis: the Controlled Substances Act does not expressly preempt California's consumer protection laws applicable to cannabis transactions; implied preemption (conflict preemption or field preemption) is unavailable because California's CLRA § 1780 claim does not require the plaintiff to establish that the cannabis sale was lawful under federal law — the claim turns entirely on California state law standards for service provider credential misrepresentation and product quality misrepresentation; (3) California has exercised its state police power under the Tenth Amendment to establish a comprehensive cannabis regulatory framework (MAUCRSA) for California consumers, and the CLRA § 1780 consumer protection claim is an exercise of California's state law authority to protect California consumers within that state regulatory framework — a domain in which federal preemption has not been asserted by Congress through any enacted legislation; (4) the federal enforcement posture under the Cole Memorandum framework (Department of Justice guidance issued August 29, 2013, outlining prosecutorial priorities for federal cannabis enforcement in states with robust regulatory systems) established a policy of federal deference to state cannabis enforcement in states with comprehensive cannabis regulatory frameworks — though the Cole Memorandum was rescinded by Attorney General Jeff Sessions in January 2018, the subsequent Blumenauer-Joyce appropriations rider language has effectively maintained Congressional restrictions on federal prosecution of state-compliant medical cannabis operations; (5) the critical legal point for the PURE KETCHUM analysis: the Controlled Substances Act creates criminal liability for Schedule I distribution under 21 U.S.C. §§ 841 and 844 — it does not create a private civil right of action for consumers harmed by unlicensed cannabis retailers; California consumers who were defrauded by unlicensed cannabis retailers, who received contaminated untested cannabis products, or who paid for cannabis goods from operators falsely representing DCC licensure have no federal court civil remedy with mandatory fee-shifting; the only mandatory fee-shifting civil consumer protection remedy available to these consumers is California's CLRA § 1780 — making the entire lodestar PURE KETCHUM, eligible for the full Ketchum v. Moses contingency multiplier with no Dague constraint whatsoever.

PURE KETCHUM — Bus. & Prof. Code § 26038 unlicensed cannabis retail practice claims with no concurrent federal statute providing mandatory civil attorney fee-shifting; no Ketchum/Dague split for the CLRA § 1780 lodestar: no federal statute creates a private right of action with mandatory attorney fees for consumers harmed by unlicensed California cannabis retailers. Cannabis is a Schedule I controlled substance under 21 U.S.C. § 812, and the Controlled Substances Act (21 U.S.C. §§ 841–860) creates criminal liability for Schedule I distribution but no private civil right of action for consumers. The Rohrabacher-Blumenauer appropriations rider (codified in successive annual appropriations acts since 2014, now the Joyce-Leahy Amendment) bars DOJ from using appropriated funds to prosecute state-compliant medical cannabis operations but creates no private civil enforcement right and no mandatory fee-shifting mechanism for consumers who purchased from unlicensed operators. No enacted federal cannabis legalization framework — not the SAFE Banking Act (which addresses financial services access for cannabis businesses, not consumer protection), not the Cannabis Administration and Opportunity Act, not the MORE Act — provides mandatory consumer civil fee-shifting for cannabis retail transactions. For the CLRA § 1780 unlicensed cannabis retailer claim, the entire lodestar from the DCC License Search date (secondary anchor) through the Tyler Odyssey complaint (primary Welch anchor) through judgment is pure Ketchum, eligible for the full Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier without any Dague v. City of Hamtramck (505 U.S. 557 (1992)) constraint on any portion of the fee award.

Primary Welch Anchor: Tyler Odyssey Civil Complaint Filing Date

The Tyler Odyssey civil complaint filing date is the primary Welch temporal anchor for the CLRA § 1780 attorney fee petition lodestar in Bus. & Prof. Code § 26038 unlicensed cannabis retail practice cases. In unlicensed cannabis retailer matters, the Tyler Odyssey complaint is typically filed after the plaintiff attorney has: confirmed through the DCC License Search that the defendant retailer or delivery service lacks a current Active DCC license for the specific commercial cannabis activity being performed at the specific location — or holds a Cancelled, Revoked, Suspended, or never-issued DCC license; reviewed the defendant's consumer-facing representations (storefront signage, website, app listings, delivery packaging) to document the specific credential misrepresentations that induced the plaintiff consumer to purchase from the unlicensed operator rather than a licensed DCC retailer; assessed the COA testing documentation — confirming (or confirming the complete absence of) DCC-licensed Type 8 laboratory COA certificates for all cannabis goods sold to the plaintiff; and evaluated the specific harm categories attributable to the defendant's unlicensed status and the related absence of mandatory product safety testing.

The pre-complaint advisory period in unlicensed cannabis retailer cases can be initiated through multiple discovery pathways: a consumer who purchased cannabis products from an operator advertising as a licensed dispensary and later learned from a news report, DCC enforcement action, or local law enforcement raid that the operator was unlicensed; a patient who purchased medical cannabis products from an unlicensed delivery service and experienced adverse health effects attributable to contaminated or mislabeled products that would not have passed mandatory COA testing; a consumer who sought to verify the licensed status of the cannabis delivery service they used after receiving products without any COA documentation or product testing labels; a consumer who learned that the "dispensary" from which they regularly purchased cannabis was operating without a DCC license after the operator was subject to DCC administrative action or local code enforcement closure; or a consumer advocacy organization or plaintiff attorney who identified a pattern of unlicensed cannabis retail operations in a geographic area following a DCC enforcement sweep and DCC public press releases announcing enforcement actions against unlicensed operators. In all these scenarios, the DCC License Search provides the definitive secondary anchor — confirming the defendant's unlicensed status as of each purchase date.

The Tyler Odyssey complaint in unlicensed cannabis retailer cases typically pleads: (1) a CLRA § 1780 claim predicated on Bus. & Prof. Code § 26038 unlicensed commercial cannabis activity — a per se misrepresentation of service provider qualifications under Civ. Code § 1770(a)(14) (credential misrepresentation) and a misrepresentation of goods' characteristics and standard under § 1770(a)(7) (COA testing deficiency — the unlicensed retailer represented or implied that its cannabis products met California's mandatory product safety standards, when in fact the products never underwent mandatory COA batch testing); (2) a UCL § 17200 unlawful business practice claim predicated on the § 26038 violation and the 4 CCR § 5724 COA testing violation — supporting injunctive relief against continued unlicensed operations and restitution of all purchase amounts paid to the unlicensed retailer; (3) a fraud or intentional misrepresentation claim based on the defendant's knowing misrepresentation of DCC licensure and product testing compliance; and (4) a negligence claim — the unlicensed retailer owed a duty to California cannabis consumers to ensure that cannabis products sold for human consumption had undergone the mandatory safety testing panel required under 4 CCR § 5724; the retailer's breach of this duty (by selling untested cannabis products from unlicensed upstream suppliers) was the proximate cause of the plaintiff consumer's exposure to pesticide residue, heavy metal, microbial, or residual solvent contamination in the purchased products, and any resulting adverse health effects.

Secondary Institutional Anchor: DCC License Search Database

The California Department of Cannabis Control License Search is the secondary institutional anchor in CLRA § 1780 unlicensed cannabis retailer practice fee petition cases — THE ONLY secondary institutional anchor in the entire fee-petition-mechanics series tied specifically to DCC's commercial cannabis licensing program. The DCC License Search covers the full spectrum of MAUCRSA commercial cannabis license types, recording each licensee's: DCC license number (the unique alphanumeric identifier assigned to each licensed commercial cannabis operation — format varies by license type, e.g., "C10-" prefix for Type 10 Retailer licenses, "C9-" prefix for Type 9 Non-Storefront Retailer licenses, allowing verification that the license type matches the specific commercial cannabis activity being performed); legal business name and DBA/trade name; license type (the specific MAUCRSA license category, critical for confirming that the defendant is licensed for the exact commercial cannabis activity at issue — a defendant operating a retail storefront requires a Type 10 Retailer license; a defendant operating a delivery-only service requires a Type 9 Non-Storefront Retailer license; a defendant operating as both a cultivator and retailer at the same premises requires a Type 12 Microbusiness license; a defendant who operates only a retail storefront but lacks a Type 10 license cannot be licensed under any other DCC license type for that retail activity); premises address (confirming that the licensed premises address matches the defendant's operating location); license issue date; expiration date (DCC cannabis licenses require annual renewal — a licensee who fails to complete the annual renewal process by the expiration date has their license status changed to Cancelled, rendering them unlicensed under § 26038 even if they previously held an Active DCC license); and current status (Active, Annual Renewal, Suspended, Revoked, or Cancelled).

When the attorney searches the DCC License Search by the defendant retailer's business name and operating address and confirms the defendant's absence from the Active licensee roster — or confirms a Cancelled, Revoked, or Suspended status as of the date the plaintiff consumer made cannabis product purchases — the search date establishes the secondary Welch anchor for the CLRA § 1780 fee petition lodestar. The attorney also performs a license type verification: if the defendant holds a DCC license for a different license type than the commercial cannabis activity at issue (e.g., holds a Type 11 Distributor license but operates a consumer retail storefront — an activity requiring a Type 10 Retailer license), the defendant is operating that specific retail activity without a DCC license in violation of § 26038, even if it holds a different DCC license type. Additionally, the attorney should cross-reference the DCC License Search result with the defendant's local jurisdiction cannabis business permit records — cities and counties in California maintain their own local cannabis business permit programs; a business may hold a local permit but no DCC state license, or hold a DCC license but no local permit — either condition constitutes unlicensed commercial cannabis activity under § 26038 and applicable local cannabis ordinances.

The DCC License Search is structurally distinct from every other California licensing database in the fee-petition-mechanics series in several important respects: unlike the DCA BreEZe modules (which cover individual professional practitioner licenses issued by specific DCA boards and bureaus), the DCC License Search covers commercial entity licenses — licenses issued to business entities (corporations, LLCs, partnerships, sole proprietors operating as businesses) rather than individual professional practitioners; unlike the CBA BreEZe module (which covers both individual CPA C-number licenses and firm FRM-number permits to practice), the DCC License Search does not distinguish individual from entity licensees because all DCC licenses are issued to the commercial cannabis business entity operating at a specific licensed premises, regardless of the individual ownership or management structure of that entity; the DCC METRC (Marijuana Enforcement Tracking Reporting Compliance) track-and-trace system provides an additional corroborating record — METRC is the state-mandated seed-to-sale tracking system required for all DCC-licensed cannabis businesses, recording the movement of cannabis goods from cultivator through distributor to retailer using unique cannabis package tags assigned at each stage of the licensed supply chain; an unlicensed retailer operates entirely outside the METRC system, with no METRC account, no package tags, and no track-and-trace records — the complete absence of METRC records for a retailer's cannabis inventory is independently corroborating evidence of unlicensed status, and METRC records (obtained through DCC public records requests or subpoena of DCC enforcement records) can confirm that the cannabis goods sold by the unlicensed retailer entered the market outside the licensed distribution chain and therefore without COA batch testing from any DCC-licensed Type 8 testing laboratory.

Billing Gap 1 — DCC License Search Database Verification, § 26038 Unlicensed Commercial Cannabis Activity Analysis, COA Testing Records Review, and Product Contamination Harm Documentation (5.00 hrs/yr = $1,500–$2,500)

The first billing gap arises in the pre-complaint advisory phase — from initial client contact through Tyler Odyssey complaint filing — during which the attorney searches the DCC License Search, confirms the defendant retailer's unlicensed status, reviews the absence of COA documentation for the cannabis goods sold to the plaintiff consumer, and documents the specific product contamination harm categories to which the plaintiff was exposed by purchasing untested cannabis products from an unlicensed retailer.

• Searching DCC License Search by business name, address, and operating entity name; verifying license type (retailer, delivery, microbusiness) matches the specific commercial cannabis activities performed; confirming issue date, expiration date, and current Active/Cancelled/Revoked status; cross-referencing with CDTFA cannabis cultivation tax records (if accessible) and local jurisdiction cannabis business permit records (cities and counties in California maintain their own local cannabis business permit databases — a business with a local permit but no DCC state license is still operating in violation of § 26038): the attorney performs the DCC License Search using multiple search parameters — the defendant's public-facing business name (the name on the storefront signage, website, or delivery app listing), the operating address (the retail storefront address or the business address used on the delivery service's registration), and any legal entity name that may differ from the DBA/trade name; the attorney confirms that the defendant's specific commercial cannabis activity (storefront retail, delivery-only, or multi-activity microbusiness) requires the corresponding DCC license type and verifies whether the defendant holds an Active license of that specific type for that specific premises; the attorney also reviews the defendant's license expiration date — an operator whose DCC license expired without renewal is engaged in unlicensed commercial cannabis activity under § 26038 from the expiration date forward, even if it previously held a valid DCC license; the attorney cross-references the DCC License Search result with the relevant local jurisdiction's cannabis business permit database (many California cities and counties maintain online portals for their local cannabis business permit programs, including Los Angeles, San Jose, Oakland, Sacramento, San Diego, and others) to confirm whether the defendant holds any form of local authorization — the presence of a local permit but absence of DCC state licensure still constitutes a § 26038 violation; if CDTFA cannabis cultivation tax records are accessible through public records request, the attorney reviews whether the defendant has filed and paid the required cannabis cultivation tax under Revenue and Taxation Code § 34012, which would be evidence of some participation in the supply chain, albeit without DCC licensure for the retail activity.
• Reviewing COA (Certificate of Analysis) records: requesting from the defendant retailer all COA documents for all cannabis goods sold to the plaintiff; confirming (or confirming the absence of) DCC-licensed Type 8 testing laboratory COA certificates; analyzing COA results for pesticide residue, heavy metals, microbial contaminants, and residual solvents exceeding 4 CCR § 5724 action levels — documenting the specific contamination categories to which the plaintiff consumer was exposed due to the unlicensed retailer's absence of COA-testing requirements: the attorney sends a pre-complaint demand or litigation hold letter to the defendant unlicensed retailer requesting production of all COA documents for all cannabis goods sold to the plaintiff during the relevant purchase period; in virtually all unlicensed cannabis retailer cases, the defendant will be unable to produce any COA documents because: (a) the defendant purchased cannabis goods from unlicensed cultivators and manufacturers who did not obtain DCC-licensed Type 8 testing laboratory COA certificates; (b) the cannabis goods purchased by the unlicensed retailer entered the supply chain outside the DCC-licensed distribution network and therefore bypassed the mandatory distribution-stage COA verification required under MAUCRSA; the attorney documents the complete absence of COA records as an affirmative product safety harm — every cannabis batch sold by the unlicensed retailer was sold without the mandatory pesticide, heavy metal, microbial, mycotoxin, residual solvent, water activity, and potency testing required under 4 CCR § 5724; if the plaintiff consumer can identify the specific cannabis products purchased (through purchase receipts, product packaging, menu screenshots from the unlicensed retailer's website, or order confirmation communications), the attorney documents the specific contamination categories to which the plaintiff was exposed — particularly the pesticide residue exposure risk (from prohibited pesticides including myclobutanil, bifenazate, abamectin, chlorpyrifos, and spiromesifen commonly used in unregulated cannabis cultivation) and the microbial contamination risk for immunocompromised consumers who used cannabis for symptom management.
• Documenting the plaintiff consumer's specific cannabis product purchases — purchase receipts, digital payment records, text/email confirmation of delivery orders, menu screenshots from the unlicensed retailer's website or cannabis marketplace listing — and correlating purchases with any adverse health effects (respiratory symptoms, allergic reactions, poisoning presentations) attributable to contaminated products from the unlicensed retailer: the attorney works with the plaintiff consumer to compile the complete purchase documentation — cash register receipts (many unlicensed retailers operate primarily in cash to avoid state cannabis excise tax collection obligations and to avoid financial institution records that would document unlicensed cannabis revenue), Venmo/CashApp/Zelle digital payment records (unlicensed delivery services routinely use peer-to-peer payment apps rather than cannabis-specific point-of-sale systems), text message confirmations of delivery orders and order confirmations, screenshots from the unlicensed retailer's website or third-party cannabis marketplace listing (Weedmaps, which has historically listed both licensed and unlicensed cannabis retailers, though DCC has pursued enforcement cooperation agreements with online cannabis marketplaces to de-list unlicensed operators), photographs of product packaging (unlicensed cannabis products often lack the California universal symbol warning label, the DCC license number, the "CA WARNING:" consumer advisory label, and the batch/lot number required under MAUCRSA packaging regulations), and any adverse health effect documentation (emergency room records, urgent care records, toxicology reports) that the plaintiff experienced after consuming cannabis products purchased from the unlicensed retailer and that may be attributable to pesticide residue, heavy metal, microbial pathogen, or mycotoxin contamination in the untested products.

Billing Gap 2 — Active Litigation and CLRA § 1780 Fee Petition — Discovery from Unlicensed Retailer, DCC Enforcement Coordination, COA Expert Toxicologist Retention, Ketchum v. Moses Multiplier Briefing, and Missouri v. Jenkins Fees-on-Fees (8.25 hrs/yr = $2,475–$4,125)

The second billing gap arises from the combined active litigation and CLRA § 1780 mandatory attorney fee petition phase — from Tyler Odyssey complaint through trial or settlement and the post-judgment fee petition — during which the attorney conducts discovery from the defendant unlicensed retailer and upstream unlicensed suppliers, coordinates with the DCC Enforcement Division, retains a toxicologist/analytical chemist expert to address the COA testing deficiency and contamination harm, prepares the complete lodestar documentation, and briefs the Ketchum multiplier with emphasis on the COA testing deficiency analysis complexity and PURE KETCHUM status.

• Conducting discovery from the unlicensed cannabis retailer: all purchase records (METRC-equivalents if any — unlicensed retailers operate outside METRC; discover paper or digital sales records), all COA documents or absence thereof for cannabis goods sold, supplier chain records (who cultivated, manufactured, and distributed the cannabis goods to the unlicensed retailer — each upstream unlicensed supplier is also a § 26038 violator and a potential co-defendant under UCL § 17200), and any communications with local code enforcement, DCC, or CDTFA concerning cannabis licensing status; coordinating with DCC Enforcement Division (complaint to DCC Enforcement for unlicensed commercial cannabis activity) to obtain DCC investigation records — DCC notice of action, DCC cease-and-desist order, DCC administrative penalty records — as corroborating evidence of § 26038 violation predicate: the attorney conducts discovery targeting the defendant unlicensed retailer to obtain: (a) all cannabis product purchase and sales records — the defendant unlicensed retailer's complete records of cannabis goods purchased for resale, including invoices from cultivators and manufacturers (all of whom are likely also operating without DCC licensure), cannabis product manifests (the DCC-licensed supply chain uses standardized manifests that accompany all cannabis goods in distribution; unlicensed supply chains typically lack standardized manifests, and any informal purchase invoices or manifests from the unlicensed supply chain establish the absence of METRC compliance and COA testing), and point-of-sale records or cash transaction logs documenting sales to consumers including the plaintiff; (b) all COA documents in the defendant's possession for any cannabis goods it purchased and sold — the complete absence of COA documents is itself a critical discovery result, establishing as a factual matter that the defendant sold cannabis goods to the plaintiff consumer without any mandatory batch testing documentation; (c) the defendant's complete supplier chain — identifying each cultivator, manufacturer, and (if any) distributor in the unlicensed supply chain from which the defendant purchased cannabis goods; each upstream unlicensed supplier is independently a § 26038 violator and may be joined as a co-defendant under UCL § 17200 unlawful business practice theories; (d) communications between the defendant and DCC, CDTFA, local code enforcement, or local law enforcement concerning the defendant's cannabis licensing status — DCC notices of violation, cease-and-desist orders, administrative penalty citations, and local permit enforcement actions all constitute admissions by conduct that the defendant was aware of the licensing requirement; the attorney simultaneously files a complaint with the DCC Enforcement Division (via the DCC's online complaint portal) reporting the specific unlicensed commercial cannabis operation and requesting DCC investigation records — DCC investigation findings, DCC notices of action, and DCC cease-and-desist orders are public DCC enforcement records that corroborate the § 26038 violation predicate and establish DCC institutional confirmation of the defendant's unlicensed status as a government record.
• Retaining a toxicologist/analytical chemist expert (with cannabis COA analysis expertise) to: (a) interpret the absence of COA testing records as a material product safety deficiency under 4 CCR § 5724; (b) if testing of retained product samples is possible, conduct or arrange independent DCC-licensed Type 8 testing laboratory analysis to determine actual contamination levels in products purchased from the unlicensed retailer; (c) opine on the specific health risks posed to the plaintiff consumer by the identified or reasonably foreseeable contamination categories (pesticide residue exposure risk, heavy metal bioaccumulation risk, microbial pathogen infection risk for immunocompromised consumers) — supporting actual damages and the negligence count: the attorney retains a qualified toxicologist/analytical chemist expert with specific expertise in cannabis product safety and California's mandatory COA testing panel under 4 CCR § 5724; the expert's responsibilities include: (a) providing an affirmative expert opinion that the defendant unlicensed retailer's failure to ensure mandatory COA batch testing of all cannabis goods sold to the plaintiff constitutes a material product safety deficiency under 4 CCR § 5724 — explaining the specific regulatory requirements, the mandatory testing panel scope, the action levels for each contamination category, and the consumer health protection purpose of the mandatory testing framework; (b) if the plaintiff has retained any cannabis product purchased from the unlicensed retailer (unopened packaging, partial product), arranging independent testing at a DCC-licensed Type 8 testing laboratory to determine the actual contamination profile of retained product samples — actual contamination testing results, if available, transform the negligence count from a theoretical risk analysis to an established contamination harm, dramatically increasing the damages available and the Ketchum multiplier weight; (c) opining on the specific health risks posed to the plaintiff consumer by the identified contamination categories — pesticide residue risk (particularly myclobutanil, which generates hydrogen cyanide upon combustion; bifenazate; abamectin; chlorpyrifos), heavy metal bioaccumulation risk (particularly lead and arsenic), microbial pathogen infection risk (particularly Aspergillus species for immunocompromised consumers), and mycotoxin exposure risk (aflatoxins, ochratoxin A) — in terms that support both the CLRA § 1780 product misrepresentation claim and the negligence count's causation and damages elements; (d) providing a regulatory compliance opinion on the complete breakdown of California's licensed cannabis supply chain safety protections when an unlicensed retailer sources products from an unlicensed supply chain — explaining the mandatory distribution-stage COA verification requirements that prevent untested products from reaching licensed retailers, and establishing that the unlicensed retailer's operation outside the licensed supply chain inevitably delivers products without these consumer safety protections.
• Documenting the complete CLRA § 1780 lodestar from DCC License Search date (secondary anchor) through Tyler Odyssey complaint (primary anchor) through judgment; briefing the Ketchum v. Moses contingency multiplier with emphasis on: (a) the COA testing deficiency analysis complexity premium (requiring simultaneous state cannabis regulatory law analysis, toxicology expert coordination, and product contamination harm documentation); (b) the PURE KETCHUM status (no federal cannabis consumer protection mandatory fee statute; no Dague constraint); (c) the PLCM Group market rate analysis for solo California consumer protection attorneys handling DCC § 26038 / CLRA § 1780 unlicensed cannabis retailer cases with COA toxicology expert coordination; Missouri v. Jenkins fees-on-fees for all fee petition preparation time: the attorney documents the complete CLRA § 1780 fee petition lodestar beginning with the DCC License Search session (the secondary Welch anchor date on which the defendant's unlicensed status was first confirmed through the DCC's official license verification portal), proceeding through the Tyler Odyssey complaint filing (the primary Welch anchor), active litigation (discovery, expert retention, deposition of defendant on DCC license status and COA testing practices, trial preparation), and through judgment; the Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier analysis for unlicensed cannabis retailer cases with COA testing deficiency and toxicology expert coordination has several compelling dimensions: (a) the COA testing deficiency analysis complexity premium — simultaneously analyzing California cannabis regulatory law (MAUCRSA, 4 CCR § 5724, DCC licensing requirements), coordinating with a specialized cannabis COA toxicology expert, and documenting product contamination harm categories requires expertise that is not routinely demanded in standard consumer protection cases and that commands a premium above the general consumer protection plaintiff bar rate; (b) the dual-jurisdiction enforcement context complexity — navigating the federal Schedule I controlled substance status of the defendant's unlicensed activity while maintaining California CLRA § 1780 consumer protection claims requires familiarity with both state cannabis regulatory law and federal preemption analysis that is a specialized premium matter; (c) the PURE KETCHUM status — the entire CLRA § 1780 lodestar is eligible for the full contingency multiplier under Ketchum without any Dague constraint, because no federal statute (not the Controlled Substances Act, not the Joyce-Leahy appropriations rider, not any enacted federal cannabis legalization legislation) creates a parallel mandatory fee-shifting mechanism for California cannabis consumers harmed by unlicensed retailers — the PURE KETCHUM status means no portion of the lodestar must be segregated as Dague-constrained; the PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)) market rate analysis documents the prevailing hourly rate in the California legal community for a solo practitioner handling CLRA § 1780 unlicensed cannabis retailer cases with DCC License Search verification, COA testing deficiency analysis, toxicology expert coordination, and DCC enforcement record integration — a rate reflecting the general California consumer protection plaintiff bar market rate adjusted for the specialized premium for proficiency in California cannabis regulatory law (MAUCRSA, 4 CCR § 5724, DCC licensing structure), the dual-jurisdiction federal preemption analysis unique to cannabis cases, and the COA testing deficiency and product contamination harm dimensions that require toxicology expert coordination; Missouri v. Jenkins (491 U.S. 274 (1989)) fees-on-fees recovery encompasses all time preparing the CLRA § 1780 fee petition — the DCC License Search narrative, the secondary anchor establishment chronology, the COA testing deficiency analysis, the toxicology expert coordination documentation, the dual-jurisdiction enforcement context analysis, the Ketchum multiplier briefing, the PLCM Group market rate affidavit, and all reply briefing responding to the defendant's fee petition opposition.

Total Annual Billing Gap — Two-Gap Summary

• Gap 1 (DCC License Search, § 26038 analysis, COA records review, product contamination harm documentation): 5.00 hrs = $1,500–$2,500/yr
• Gap 2 (active litigation, discovery, DCC enforcement coordination, toxicologist expert retention, CLRA § 1780 fee petition, Ketchum v. Moses multiplier briefing): 8.25 hrs = $2,475–$4,125/yr
• Total: 13.25 hrs = $3,975–$6,625/yr untracked at $300–$500/hr median California solo practitioner rate

Related California Attorney Fee Petition Pages

• California CLRA — Consumer Legal Remedies Act — Civ. Code § 1780
• California Anti-Price-Gouging — Penal Code § 396
• California Telephonic Sellers Act — Bus. & Prof. Code § 17511